Study
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001004657 | Other |
Study Description
Profiling of circulating tumor DNA (ctDNA) may offer a non-invasive approach to monitor disease progression. Here, we developed a quantitative method, exploiting local tissue-specific cell-free DNA (cfDNA) degradation patterns, that accurately estimates ctDNA burden independent of genomic aberrations. Nucleosome-dependent cfDNA degradation at promoters and first exon-intron junctions was strongly associated with differential transcriptional activity in tumors and blood. A quantitative model, based on just 6 regulatory regions, could accurately predict ctDNA levels in colorectal cancer patients. Strikingly, a model restricted to blood-specific regulatory regions could predict ctDNA levels across both colorectal and breast cancer patients.
Study Datasets 4 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001006419 |
WGS data of plasma samples from CRC patients (N=12)
|
Illumina HiSeq 4000 | 12 |
| EGAD00001006420 |
WGS data of plasma samples from BRCA patients (N=10)
|
Illumina HiSeq 4000 | 10 |
| EGAD00001006421 |
WGS data of plasma samples from healthy individuals (N=29)
|
Illumina HiSeq 4000 | 29 |
| EGAD00001008352 |
WGS data of buffy coat from CRC patients
|
Illumina HiSeq 4000 | 7 |
Who archives the data?
Publications
Citations
Retrieving...
Retrieving...
